Vena Cava Filter for All Patients After Severe Trauma

Until today, there was no evidence warranting the early implantation of a vena cava filter for the reduction of the risk of pulmonary embolism in patients with severe trauma and contraindication to prophylactic anticoagulation.

This article, soon to be published in the New England Medical Journal (NEJM), brings us such evidence and we surrender to it. Early prophylactic placement of a vena cava filter after severe trauma did not reduce the incidence of symptomatic pulmonary embolism or death at 90 days compared with no implantation of a filter.

This multicenter controlled trial enrolled 240 patients with severe trauma (Injury Severity Score >15; scores range from 0 to 75, and the highest the score, the highest the severity]) who had a contraindication to anticoagulation, and randomized them to filter implantation within the first 72 hours after admission vs. no implantation.


Read also: New Promising Alternatives for Mitral Regurgitation.


The primary endpoint was a composite of symptomatic pulmonary embolism at 8 to 90 days in the subgroup of patients who survived at least 7 days and who did not receive prophylactic anticoagulation during that time.

The mean age was 39 years old and the mean Injury Severity Score was 27.

Early filter implantation did not result in lower incidence of the primary endpoint (13.9% in the vena cava filter group vs. 14.4% in the control group; p = 0.98).

No patient in the filter group developed pulmonary embolism while 5 patients (14.7%) in the control group, including one who died, did experience such complication. Entrapped thrombus was found in the filter in 6 patients.

Conclusion

Early prophylactic placement of a vena cava filter in patients with severe trauma did not result in a lower incidence of symptomatic pulmonary embolism or death at 90 days vs. no filter implantation in patients with contraindication to prophylactic anticoagulation.

Original Title: A Multicenter Trial of Vena Cava Filters in Severely Injured Patients.

Reference: Kwok M. Ho et al. N Engl J Med. 2019 Jul 7. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...